Alirocumab: targeting PCSK9 to treat hypercholesterolemia.

• Autores: E. Pecin, Z. Reiner
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 51, Nº. 12, 2015, págs. 681-688
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Lowering of low-density lipoprotein (LDL) cholesterol reduces coronary heart disease morbidity and mortality, not only in secondary but also in primary prevention. Statins are generally accepted as a treatment of choice for this. However, still many high-risk and very-high-risk patients fail to achieve target LDL cholesterol values. Therefore, a new class of lipid-lowering drugs was recently developed-inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab was the first drug in this class to be approved by the U.S. Food and Drug Administration (FDA) and recently also by the European Medicines Agency (EMA). Alirocumab has been shown to lower LDL cholesterol by up to 60% with a safety profile comparable to that of placebo. Large outcome studies are still on the way and their first results will be available in 2017. This review focuses on alirocumab, discussing currently available hard evidence on the beneficial effects of this drug in the treatment of hypercholesterolemia.